London’s Candide will continue to cultivate his satirical garden! Originally only scheduled to play a limited run through February 22, London’s Candide will now play eight additional performances. Directed by Matthew White and choreographed by Adam Cooper, the show will close at the Menier Chocolate Factory on March 1. View Comments Candide originally opened on Broadway in December 1956, starring Robert Rounseville as Candide and Barbara Cook as Cunegonde. It was nominated for five Tony Awards, including Best Musical. The cast of Candide features Fra Fee as Candide, Scarlett Strallen as Cunegonde, Jackie Clune as the Old Lady, James Dreyfus as Dr. Pangloss, David Thaxton as Maximilian, Cassidy Janson as Paquette and Ben Lewis as Govenor and Vanderdendur. The satirical operetta tells the story of Candide’s journey of discovery, from Westphalia to the far reaches of the New World. Through anguish, happiness, loss and love, Candide is a whirlwind adventure that seeks to prove “life is happiness indeed.” The show features classic songs “Glitter and Be Gay” and “Make Our Garden Grow.”
From late summer into fall, Southerners start looking for muscadines — a popular grape native to the Southeastern U.S. Selections run from the dark purple, thick-skinned traditional muscadine to a light golden-green variety. Soon, growers and consumers can add a new red variety to the mix.The University of Georgia College of Agricultural and Environmental Sciences’ muscadine grape team, led by horticulture Professor Patrick J. Conner, developed a variety of muscadine for those who prefer the sweet taste of a berry with limited muscadine flavor.“The unusual red color of this berry really makes it stand out,” Conner said. “But the tender skin and crisp flesh of this variety are what truly make it unique. The texture of this variety is a marked change from traditional muscadines, which are often known for having tough skins and a soft pulp.” Researchers found ‘RubyCrisp’ to be a good fit for pick-your-own operations and home gardens because of its distinctive taste and texture and excellent productivity. Unfortunately, commercial production is not a good fit for this specialized berry, because it often cracks with rough handling. However, ‘RubyCrisp’ vines can flourish in the backyards of at-home cultivators looking to try the newest muscadine.‘RubyCrisp’ originated in Tifton, Georgia, as a result of a cross between ‘Supreme’ and ‘Tara’ varieties. ‘Supreme’ produces black berries with exceptional size and firmness. ‘Tara’ produces bronze berries with dry pedicel scars that ripen early in the muscadine harvest season. In 2011 the ‘RubyCrisp’ vine was chosen because of its large berry size, flower type and outstanding flavor.The original ‘RubyCrisp’ vines were tested on UGA experiment plots in Tifton and at a commercial vineyard in Wray, Georgia. There, researchers discovered that given the large berry size and high production potential of ‘RubyCrisp’, growers may need to limit vine fruitfulness by increasing the distance between fruiting spurs or thinning the crop so that the vine is not weakened by maturing excessive crops. UGA researchers also found that heavy rainfall can lead to fruit cracking. ‘RubyCrisp’ has a mid-season harvest date around Aug. 21 in south Georgia and has perfect flowers so it does not need a pollinator.“Because further study is needed to explore the optimum environment for producing this vine, especially its cold hardiness, we suggest growers in northern muscadine regions refrain from planting large numbers of ‘RubyCrisp’ until more data is collected,” Conner said.UGA has the oldest muscadine breeding program in the U.S. The program began in 1909, and since then, it has released over 30 cultivars and counting. The program focuses on continued improvement of the muscadine grape by developing new cultivars that satisfy the needs of growers and the demands on consumers. The UGA muscadine breeding program works to create new cultivars that combine large berry size with perfect flowers, expand the harvest season with earlier and later ripening dates, and produce berries with dry stem scars, crisp flesh and tender skins.A list of nurseries licensed to propagate ‘RubyCrisp’ muscadine is available by contacting Conner at firstname.lastname@example.org. For more information about the UGA muscadine grape breeding program, visit muscadines.caes.uga.edu.
FacebookTwitterLinkedInEmailPrint分享Globe and Mail:Environment Minister Catherine McKenna and her British counterpart, Claire Perry, will launch an international alliance to phase out coal-fired electricity at the Bonn climate summit this week, signalling a sharp contrast to U.S. President Donald Trump’s promotion of coal as an important global energy source.Ms. McKenna will take the stage at the annual United Nations climate summit to showcase Canada’s efforts to reduce greenhouse gas (GHG) emissions, including a national carbon pricing plan and federal-provincial moves to shut down traditional coal-fired power by 2030.The United States, meanwhile, will use its platform at Bonn to highlight the Trump administration’s support for coal and other fossil fuels. At a Monday event, U.S. officials will join industry representatives at a panel discussion on “the role of cleaner and more efficient fossil fuels and nuclear power in climate mitigation.”U.S. Energy Secretary Rick Perry is proposing an American-led alliance that would encourage developing countries to invest in more efficient coal plants. In contrast, Ms. McKenna and Ms. Perry will tout their countries’ plans to phase out coal-fired power as a model for the world and will aim to rally international investors to finance lower-carbon options rather than coal.Since concluding a federal-provincial climate deal last December, Ottawa has announced a ream of planned policies to reduce GHG emissions, but it has yet to introduce the legislation or regulations to implement them, while the bulk of planned spending won’t come for another year or two.In a fall report, federal Environmental Commissioner Julie Gelfand said the government must speed up the implementation of its plan.The Liberals face criticism from two sides. New Democratic Party MP Linda Duncan says the Liberals are not moving fast enough, noting the 2017 budget indicated major spending on critical emission-reduction programs won’t begin until 2018-19.Conservative Party MP Ed Fast argues the Liberals are piling on climate-related costs, including carbon taxes, at the risk of the country’s industrial competitiveness. He said Canada cannot get too far out of line with its major trading partners such as the United States, particularly at a time when Mr. Trump is pursuing a pro-business agenda.The Trudeau government achieved a major victory just a year into its mandate by securing provincial and territorial agreement on the Pan-Canadian Framework on climate change, which commits all governments to undertake a broad range of policies – including carbon pricing – to bring down emissions.Ms. McKenna insisted her government is not slackening the pace but taking a reasonable time to consult with industry and environmental experts on legislation and regulations, while working with provinces and territories on priorities for spending that will have the greatest impact on emissions.“We are absolutely on track to meet our 2030 commitments,” she said. “We have a plan … and there’s a whole variety of measures we need to be taking. We also aren’t doing this alone; we’re working with provinces and territories.”She pointed to federal investment in transit, including up to $1-billion over several years for Ottawa’s light rail transit system, a project which she said would result in the largest GHG reduction in the city’s history.Carbon pricing legislation will be introduced early in the new year and will require all provinces to meet a minimum federal standard or see Ottawa implement its own carbon tax in their jurisdiction. The federal plan to reduce methane emissions in the oil and gas industry is due to be released soon, even as Alberta is expected to release its own draft regulations in the coming days.More: Canada, Britain to tout coal phase-out as U.S. champions fossil fuels In Coal Phase-Outs, Canada and U.K. Part With U.S.
Sign up for our COVID-19 newsletter to stay up-to-date on the latest coronavirus news throughout New York This story was co-published with NPR’s Shots blog.This story has been updated.Few days went by last year when New Hampshire nephrologist Ana Stankovic didn’t receive a payment from a drug company.What the New ‘Collaborative Media’ Can MeanOur Dollars for Docs Database Search through nearly 15 million records to see if your doctor has received money from a drug or device company. Search for your physician.All told, 29 different pharmaceutical companies paid her $594,363 in 2014, mostly for promotional speaking and consulting, but also for travel expenses and meals, according to data released Tuesday detailing payments by drug and device companies to U.S. doctors and teaching hospitals. (You can search for your doctor on ProPublica’s updated Dollars for Docs interactive database.)Stankovic’s earnings were certainly high, ranking her about 250th among 606,000 doctors who received payments nationwide last year. What was more remarkable, though, was that she received payments on 242 different days — nearly every workday of last year.Reached by telephone Tuesday, Stankovic declined to comment. On her LinkedIn page, Stankovic lists herself as vice chief of staff at Parkland Medical Center HCA Inc. in Derry, New Hampshire, and as medical director of peritoneal dialysis at DaVita Inc., also in Derry.That doctors receive big money from the pharmaceutical industry is no surprise. The new data released by the Centers for Medicare and Medicaid Services shows that such interactions are widespread, with not only doctors, but thousands of dentists, optometrists, podiatrists and chiropractors receiving at least one industry payment from August 2013 to December 2014.What is being seen for the first time now is how ingrained pharmaceutical companies and their sales reps are in the lives of those who write prescriptions for their products. A ProPublica analysis found that 768 doctors received payments on more than half of the days in 2014. More than 14,600 doctors received payments on at least 100 days in 2014.Take Juichih Hsu, a Maryland doctor whose specialty is family medicine. She received payments on 286 days of 365, more than anyone else. Sometimes, she received meals from several drug companies on the same day. Hsu’s payments totaled $5,959 in 2014. She declined to comment when reached on Tuesday.“There are physician practices which have very deep relationships with pharmaceutical representatives, where they are a very integral part of the practice,” said Dr. Aaron Kesselheim, an associate professor of medicine at Harvard Medical School who has written about industry relationships with doctors. “Every day it’s another drug company coming in for a lunch. Sometimes it may be some drug companies are bringing breakfast and some are bringing lunch and it’s just part of the culture of the practice.”Sometimes there may be more at work than that.Source: Centers for Medicare and Medicaid ServicesGraphic by: Cecilia Reyes/ProPublicaThe doctor with the second-highest number of interactions with drug and device reps, John Fritz, of Jersey City, N.J., logged payments on 256 days last year. His payments totaled $232,003. Fritz was indicted in June for referring patients to a medical imaging company from 2006 to 2013 in exchange for about $500,000 in kickbacks. He was charged with fraud and bribery, according to a release from the state attorney general’s office. A woman who answered the phone at his office on Tuesday said he declined to comment.Kesselheim said that to have such extensive contact with industry reps can indicate that doctors are getting their information about the drugs they prescribe from the companies that make them, and not from impartial sources. “There’s good evidence that that affects prescribing practices and physician behavior.”The drugs for which Stankovic received the most money to promote are costly. One, H.P. Acthar Gel, cost an average of nearly $39,000 a prescription, Medicare data from 2013 shows, and experts say there’s little evidence it works better than less expensive drugs. Another drug, Soliris, for which Stankovic received promotional payments is among the most expensive drugs in the world but is considered highly effective in treating serious kidney disease.ProPublica’s analysis turned up big differences in the number of industry interactions among physicians in different specialties. On average, doctors who received payments interacted with drug and device companies on 14 days last year, receiving an average of $3,325 in total.The nation’s 3,900 rheumatologists in the data averaged 40 days of interactions with drug and device companies, more than doctors in any other large specialty. They were followed closely by endocrinologists, electrophysiologists and interventional cardiologists. On the other end of the spectrum, dentists, chiropractors, neonatologists and pathologists had among the fewest interactions with drug and device makers.Some of the doctors who had the highest number of interactions were those ProPublica has previously identified as having high rates of brand-name prescribing in Medicare’s prescription drug program, known as Part D. Others have been mentioned in previous ProPublica stories about doctors who have received large payments from the drug industry. A number of experts, including Kesselheim, note that payments from industry may influence physicians’ choice of drugs.A spokeswoman for the pharmaceutical industry said in a statement that company interactions with doctors are important.“Collaboration between physicians and biopharmaceutical professionals is critical to improving the health and quality of life of patients,” the statement from the Pharmaceutical Research and Manufacturers of America said. “Clinical trials sponsored by biopharmaceutical companies have led to life-saving breakthroughs for people suffering from cancer and other life-threatening diseases. Physicians also provide real-world insights and valuable feedback to companies about their medicines to improve patient care. Educating the public about the nature of these collaborations helps patients understand in which ways these interactions can improve both their health and medical innovation.”ProPublica has been tracking industry payments to doctors since 2010. Our Dollars for Docs interactive database allowed people to search payments made by 17 companies between 2009 and 2013. Most of those companies were required to report their payments as a condition of legal settlements with the federal government.The data released Tuesday radically expands the amount of data available to patients — and ProPublica has overhauled Dollars for Docs to include these payments. The Physician Payment Sunshine Act, a part of the 2010 Affordable Care Act, mandated that all drug and device companies publicly report payments to doctors. The transparency effort is called Open Payments.The government initially released some data last fall, covering the period of August to December 2013, but it was significantly redacted because of data inconsistencies. The data released Tuesday covers the period of August 2013 to December 2014. The data inconsistencies have been resolved.All told, 1,617 companies reported 15.7 million payments valued at $9.9 billion. Nearly all of those payments — 14.9 million — were classified as “general payments,” covering promotional speaking, consulting, meals, travel and royalties. They totaled $3.5 billion over the 17-month period.Source: Centers for Medicare and Medicaid ServicesGraphic by: Cecilia Reyes/ProPublicaCorrection, July 2, 2015: This graphic included incorrect numbers for “Gift” and “Nonaccredited Training.” They have been corrected.There were far fewer research payments, 826,000, but they were valued at $4.8 billion. The remaining payments related to ownership or investment interests that doctors had in companies. Research and ownership payments are currently not shown in Dollars for Docs.Open Payments does not include money spent on drug samples left at doctors’ offices and doesn’t include the bulk of the money companies spend on independently administered continuing medical education, which they support with unrestricted grants. The government has tightened the rules for reporting such continuing education in the future.From August 2013 to December 2014, Genentech Inc. spent the most on general payments, $387.7 million, mostly royalties for its drugs Rituxan, Avastin and Herceptin to City of Hope National Medical Center in Duarte, California. That was four times more than the second-ranked company, DePuy Synthes Products LLC, which spent $94.7 million, nearly all on royalties. Topera Inc., a small medical device company, came in third, with $93.1 million, almost exclusively acquisition payments to its physician founders from device maker Abbott Laboratories.Among other pharmaceutical companies, AstraZeneca spent the most on general payments ($90.9 million), followed by Pfizer ($82.1 million) and Allergan ($70.7 million). In a statement, AstraZeneca said that it believes “it is important to be open about the way we conduct our business and how we help people through our medicines and programs. We are committed to the highest standards of conduct in all of our operations, including how we partner with physicians and medical institutions.”Royalty fees, though few in number, accounted for $803.5 million in general payment spending in 2014, more than any other category. They were followed by promotional speaking ($632.4 million) and consulting ($369.4 million). Food and beverages accounted for the highest number of payments by far, 9.4 million, but these had a relatively low value of $224.5 million.ProPublica news application developers Mike Tigas and Lena Groeger and senior reporting fellow Annie Waldman contributed to this report.Update, July 8, 2015: Although Stankovic declined to comment for the initial story, she has now provided the following statement: “I am very passionate about clinical research and up to date medical information; and truly enjoy educating medical professionals on various complicated disease states. There is so much new information to be learned every day in medicine, but simply there is no enough time during the day, especially if provider has a busy medical practice. Many of the interactions that doctors have with pharmaceutical industry are needed in order to stay current with newer FDA approved therapies that may cure illnesses or slow progression of the complicated diseases. Patients should be able to appreciate those medical professionals who can thoroughly discuss all available treatment options on the market and warn them about possible side effects and contraindications.”Correction, July 2, 2015: This post has been corrected to change the average amount doctors received in payments in 2014. The graphic has also been corrected.Check Dollars for Docs to see whether your doctor has received payments from drug or medical device companies. Email us at email@example.com and tell us what you find.ProPublica is a Pulitzer Prize-winning investigative newsroom. Sign up for their newsletter.
The key place to look for them is your employees.by: Scott McClymondsOne of the first ideas to embrace as a leader is the fact that somewhere in your company there are tens of thousands, maybe even millions of dollars of profitability locked up needlessly in legacy processes, outdated technology, or underutilized assets. A critical part of your job is to constantly be on the lookout for these untapped pockets of opportunity and find ways to unleash them.This article will help you consider the key aspect of unlocking hidden profitability, your employees. Without a doubt, they can be directed into more profitable actions that will also give them a greater sense of job satisfaction. These six actions aren’t exhaustive, but they should stimulate your thinking.1. Analyze job performance. Some people are stars, some may need training, and some may need to be replaced. Some stars may even need to be replaced if they are taking you in a direction different from your vision. continue reading » 4SHARESShareShareSharePrintMailGooglePinterestDiggRedditStumbleuponDeliciousBufferTumblr
Phil HaighSaturday 17 Aug 2019 2:53 pmShare this article via facebookShare this article via twitterShare this article via messengerShare this with Share this article via emailShare this article via flipboardCopy link169Shares David Luiz explains why it’s ‘a pleasure’ to have joined Arsenal from Chelsea Advertisement Advertisement David Luiz was impressive on his Arsenal debut (Picture: Getty Images)David Luiz made his Arsenal debut in a 2-1 win over Burnley on Saturday and has described joining the club from Chelsea as ‘a pleasure’.The Brazilian was impressive at centre-back for the Gunners as they secured their second win from two games at the start of the Premier League season.The 32-year-old’s £8m move from Chelsea was something of a surprise at the end of the transfer window, but the defender is delighted to have made the switch to the Emirates and link up with Unai Emery again.The pair briefly worked together at Paris Saint-Germain and Luiz is very pleased to reform the working relationship.AdvertisementAdvertisementADVERTISEMENT‘I’m so happy to be here and try to do my job and also to enjoy with these quality players,’ the defender said after the win over Burnley.‘This team has a lot to do, it can improve a lot and fight for other competitions.‘We’re going to be step-by-step, working hard and it’s a pleasure to be here because everybody’s humble, everybody wants to learn, everybody wants to improve and we want to make this club shine again.‘It’s great to feel the support from everybody, I just tried to do my best. My style is to play football and also to understand the plan for the game.’More: FootballRio Ferdinand urges Ole Gunnar Solskjaer to drop Manchester United starChelsea defender Fikayo Tomori reveals why he made U-turn over transfer deadline day moveMikel Arteta rates Thomas Partey’s chances of making his Arsenal debut vs Man CityThe Brazil international displayed the ball-playing abilities he is known for in his first appearance in an Arsenal shirt and confirmed that Emery has instructed him to pass the ball out from defence.He said: ‘We changed a bit because the game showed us to play in a different way, but when you have confidence and you train with the team, you have to do the plan and the plan is to play from the back.‘We tried to do that and in the end I think we did it very well.’Alexandre Lacazette opened the scoring in north London, before Ashley Barnes leveled things up for Burnley before the break.Arsenal went on to dominate the second half and Pierre-Emerick Aubameyang scored the winner in the 64th minute.MORE: Unai Emery explains Arsenal team selection as David Luiz and Dani Ceballos start but Mesut Ozil misses outMORE: Robin van Persie questions Unai Emery’s approach and believes Arsenal should play to their own strengths Comment
In a statement the company said: “Whilst we were disappointed and surprised by the judgment of Sir Ian Dove in dismissing our claim to the compulsory purchase order made by Haringey Council to support the stadium scheme of Tottenham Hotspur Football Club, we have decided not to appeal against his decision.” It continued: “We have always been willing to negotiate with the club on a reasonable and proper basis. Our efforts towards that end have been unsuccessful so far, but we will continue to try to achieve a proper settlement by agreement if that is possible. “Our other overriding objective is also to arrange for the relocation of our family business as quickly as possible and to preserve the jobs of those we employ.” Spurs have planning permission for the new stadium and hope it will open in time for the 2018-19 season. The London Borough of Haringey made the purchase order in March 2012, which was confirmed by the Communities Secretary in July 2014 following a public inquiry. Acknowledging the company’s decision the football club first tweeted the news, later releasing a statement on their website. It read: “The club has received confirmation that Archway Steel will not be applying to the Court of Appeal for permission to appeal the High Court’s decision last month to refuse their legal challenge of the Compulsory Purchase Order. “The next step will be to vest the land in Haringey Council’s ownership and to agree the compensation amount payable to Archway. “We shall also continue to seek to reach an agreement with Archway by private treaty. We shall provide a further update as matters progress.” Archway Sheet Metal Works, in Paxton Road, behind the club’s north stand, had its legal bid against a compulsory purchase order rejected at the High Court last month. The firm has announced that it will not be appealing the decision, meaning that Spurs can proceed with their £400 million redevelopment of White Hart Lane. Press Association Tottenham are free to go ahead with proposals to build their new stadium after a family business dropped its legal challenge to the plans.
highlights Commenting on Watson’s innings, Harbhajan said, “We would have liked to finish the game in the 19th over itself, but the boys were just testing our hearts. Somehow we have the tendency to take it to the last over. As long as we’re getting the result, we’re fine. It’s nice to see Shane Watson getting those runs under his belt. He’s a serious player; last year, he won us the final single-handedly, and this innings will boost his confidence.”It will be difficult for other teams to beat Super Kings in Chennai, Harbhajan stated. “We always play well in Chennai, we know our conditions, and thanks to this beautiful crowd who come here to Chennai Super Kings. When teams come here, they have to play much better cricket than us to beat us,” Harbhajan concluded. Chennai Super Kings upstaged Sunrisers Hyderabad on Tuesday. Chennai registered their eighth win in the ongoing edition of the Indian Premier League. Shane Watson was adjudicated as the man-of-the-match. For all the Latest Sports News News, Indian Premier League News, Download News Nation Android and iOS Mobile Apps. New Delhi : The Chennai Super Kings off-spinner, Harbhajan Singh is glad to be back in action after having been afflicted with health issues. Harbhajan picked up two wickets — dismissing David Warner and Jonny Bairstow — to aid in Chennai Super Kings’ six-wicket win over Sunrisers Hyderabad on Tuesday night.“It’s always nice to go out there in the middle, unfortunately I missed a few games due to sickness. My whole family was sick, in fact. [It’s] nice to be back, and really happy with the result as well,” Harbhajan said at the post-match presentation ceremony. Watson played a blazing knock of 96 to steer Super Kings to victory.
The announcement that a Chick-fil-A restaurant will be opening near Tuscany this summer has prompted mixed reactions from USC students.The restaurant is projected to open midsummer near the intersection of Figueroa Street and State Drive, according to a company spokesperson.“We’ve been in negotiations since summer of last year, but we were looking at property in the area long before that,” said Brenda Green, the senior public relations coordinator at Chick-fil-A. “It will definitely open in July.”Many students said they were happy to hear the popular chain would be coming to the USC area next year.“I’m excited for it to be there,” said Cat Price, a freshman majoring in political science. “All of my friends from the South always talk about Chick-fil-A, and I’ve never had it before.”Brittany La Hue, a freshman majoring in communication, said that although she likely won’t visit Chick-fil-A, she knows a number of people who will.“I probably won’t eat there often. But I know people are excited about it because it’s really good,” she said. “Before I was a vegetarian, I used to eat there all the time.”Not all students, however, are excited by the announcement and some students said there are other restaurants they would rather see in its place.“I’d like to see something that isn’t fast food,” Price said.La Hue said the lack of good Asian cuisine near campus bothers her the most.“I wish we had more options for Asian food that isn’t Panda Express,” La Hue said. “It would be nice to see a restaurant like that go into the new location.”Christian Daly, a junior majoring in English, said he might go to Chick-fil-A, but there are other restaurants he would have preferred.“I’d rather see Johnny Rockets there,” Daly said.Though many agreed Chick-fil-A will likely be popular among USC students, some said they wished the location were more convenient.“I don’t think I’ll be going there too often,” Price said. “It’s kind of out of the way.”La Hue echoed this idea.“If they had a location on campus that would be the best,” she said. “I know Figueroa is also really popular for students who have been out on The Row, but Tuscany is pretty far.”Green said Chick-fil-A does background research to ensure it doesn’t open up a store that will be a financial flop.“Whenever we build a store, we make sure that the financial model for the new location meets what we are looking for,” Green said. “So we do anticipate this being a successful store.”Students also think the restaurant will be successful.“I’ve definitely heard a lot of people talking about it, so I’m sure a good number of students will eat there,” Price said.
Similar to their first meeting this season, the No. 1 Wisconsin women’s hockey team (21-3-0, 11-3-0 WCHA) and the No. 2 Minnesota Gophers (22-3-1, 12-3-1) traded wins during their two-game series in Minneapolis. The two heavyweights remain seemingly deadlocked in both talent and execution, as neither team can manage to gain a consistent advantage over the other.Wisconsin managed to scrap its way to an opening game victory against its rival with a game-winning goal late in the second period from redshirt senior Maddie Rolfes. While this was only Rolfes’ second goal of the season, it was certainly her most valuable, as it propelled the Badgers to a decisive victory at Ridder Arena.Still, Wisconsin had to earn the win, as the Gophers rattled off 17 shots on goal following their early second-period goal from Nicole Schammel. Junior goalie Kristen Campbell came through for Wisconsin’s defense, as she managed to stop all of Minnesota’s shots following their lone goal in the opening 20 seconds of the second period.Women’s Hockey: Badgers maintain No. 1 ranking heading into final third of regular seasonThe top-ranked Wisconsin women’s hockey team (20-2-0, 10-2-0 WCHA) fell to the No. 5 ranked Ohio State Buckeyes (15-7-0, 9-5-0) Read…Saturday’s game, however, was a different story for the Badgers, who ran into an exceptional performance from Minnesota goalie Sydney Scobee. Wisconsin managed to outshoot the Gophers nearly two to one, yet netted only one goal the entire game compared to Minnesota’s three.Scobee boasted an impressive 37 saves, effectively limiting the explosive Badger offense. Other than a second-period goal from freshman Sophie Shirley, the Badgers were reined in by an impressive display of goaltending.While splitting the second edition of the Border Battle certainly wasn’t what the Badgers had hoped for, the result does not remove them from their strong position on the national stage.Men’s basketball: Happ, Wisconsin stun No. 2 Michigan in front of sold-out Kohl CenterThe University of Wisconsin men’s basketball team (12-6, 4-3 Big Ten) upset No. 2 Michigan (17-1, 6-1) 64–54 at the Read…The Badgers maintained their No. 1 national ranking, but still remain second in the WCHA standings behind Minnesota. But with more games remaining on their schedule than the Gophers, the Badgers will have ample opportunity to claim the top conference spot as long as they handle business against weaker teams that they have handily defeated this season.Moving forward, look for the Badgers to build momentum with strong performances in their upcoming series as they wrap-up their season against Minnesota State, Minnesota-Duluth and The Ohio State.